Home › Companies › Taysha Gene Therapies, Inc. › 2025-2026

Taysha Gene Therapies, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Taysha Gene Therapies, Inc.’s Form 8-K, filed 2026-06-02 (Item 5.07 on EDGAR). Page generated 04 October 2026.

7Reported items
188Asset managers
1,205Fund votes
2026-06-01Meeting date

Proxy season: 2025-2026

Explore Taysha Gene Therapies, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Taysha Gene Therapies, Inc.

These tallies are Taysha Gene Therapies, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-02 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Taysha Gene Therapies, Inc. — official shareholder meeting results, meeting held 2026-06-01
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Sean P. Nolan	169,142,295	--	--	35,742,331	--	Majority: yes
Elect Director: Laura Sepp-Lorenzino, Ph.D.	150,094,517	--	--	54,790,109	--	Majority: yes
Elect Director: Ratification of selection of Deloitte & Touche LLP	243,814,085	25,551	18,176	--	--	Majority: yes
Elect Director: Approval of the compensation of the Company's named executive officers	168,142,551	36,396,784	345,291	--	--	Majority: yes

Source: Taysha Gene Therapies, Inc., Form 8-K, filed with the SEC on 2026-06-02 — read the filing on EDGAR.

How asset managers voted at the Taysha Gene Therapies, Inc. 2025-2026 meeting

Each item below shows how the 188 asset managers that disclosed a Taysha Gene Therapies, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Taysha Gene Therapies, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 8 wordings of this item as funds reported it.

82% Majority: yes · of votes cast

FOR 82%AGAINST 18%

FOR: 168,142,551AGAINST: 36,396,784

Taysha Gene Therapies, Inc.’s own tally for this item (“Elect Director: Approval of the compensation of the Company's named executive officers”): 168,142,551 for, 36,396,784 against, per its Form 8-K filed 2026-06-02 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 287,276,885 outstanding shares: 59% for, 13% against (71% of the company cast a for/against vote).

The 183 asset managers below cast 81% of the shares they voted on this item FOR (156,074,015 for, 37,453,991 against).

FOR 81%AGAINST 19%

FOR: 156,074,015 (80.6%)AGAINST: 37,453,991 (19.4%)ABSTAIN: 106 (0.0%)

Largest asset managers voting on “TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.” at Taysha Gene Therapies, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Fidelity	26,611,815	58,700	0	For
RA CAPITAL MANAGEMENT, L.P.	23,555,648	0	0	For
Avoro Capital Advisors LLC	20,390,383	0	0	For
Vanguard	14,097,421	54,831	1	For
Vestal Point Capital, LP	0	12,119,056	0	Against
RTW INVESTMENTS, LP	11,636,054	0	0	For
BlackRock	10,688,057	98,858	0	For
Polar Capital Holdings Plc	0	10,711,870	0	Against
Octagon Capital Advisors LP	8,859,911	0	0	For
Siren, L.L.C.	8,829,913	0	0	For
State Street	5,889,453	58,098	0	For
GEODE CAPITAL MANAGEMENT, LLC	5,539,220	0	0	For
Charles Schwab	3,619,510	0	0	For
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND	0	2,883,301	0	Against
DEERFIELD MANAGEMENT COMPANY, L.P.	2,722,165	0	0	For
ADAR1 Capital Management, LLC	0	2,524,607	0	Against
Goldman Sachs	2,375,663	0	0	For
Casdin Capital, LLC	0	2,302,393	0	Against
B Group, Inc.	1,778,755	0	0	For
RICE HALL JAMES & ASSOCIATES, LLC	1,567,861	0	0	For
DE Shaw	0	1,267,887	0	Against
Northern Trust	1,059,185	23,535	0	For
Aberdeen	0	1,021,063	0	Against
Sands Capital Alternatives, LLC	724,873	0	0	For
Voya	0	598,177	0	Against

Showing the 25 largest of 183 asset managers. See all 183 in the interactive database.

2. TO INDICATE, ON A NON-BINDING ADVISORY BASIS, THE PREFERRED FREQUENCY OF FUTURE STOCKHOLDER ADVISORY VOTES ON THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.

SECTION 14A SAY-ON-PAY VOTES

Combines 5 wordings of this item as funds reported it.

98% fund support · no official result

ONE YEAR 69%1 YEAR 29%

The 181 asset managers below cast 98% of the shares they voted on this item FOR (1,961,732 for, 36,482 against).

FOR: 1,961,732 (1.1%)AGAINST: 36,482 (0.0%)ONE YEAR: 127,724,763 (69.2%)1 YEAR: 53,964,243 (29.2%)1-YEAR: 514,916 (0.3%)3 YEARS: 277,111 (0.2%)THREE YEARS: 113,491 (0.1%)2 YEARS: 4,160 (0.0%)1.0: 421 (0.0%)2.0: 1 (0.0%)

Largest asset managers voting on “TO INDICATE, ON A NON-BINDING ADVISORY BASIS, THE PREFERRED FREQUENCY OF FUTURE STOCKHOLDER ADVISORY VOTES ON ” at Taysha Gene Therapies, Inc., 2025-2026
Asset manager	For	Vote
Fidelity	0	One Year
RA CAPITAL MANAGEMENT, L.P.	0	One Year
Avoro Capital Advisors LLC	0	1 Year
Vanguard	0	One Year
Vestal Point Capital, LP	0	One Year
RTW INVESTMENTS, LP	0	One Year
BlackRock	0	1 Year
Polar Capital Holdings Plc	0	One Year
Siren, L.L.C.	0	1 Year
State Street	0	One Year
GEODE CAPITAL MANAGEMENT, LLC	0	One Year
Charles Schwab	0	1 Year
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND	0	One Year
DEERFIELD MANAGEMENT COMPANY, L.P.	0	1 Year
ADAR1 Capital Management, LLC	0	One Year
Goldman Sachs	0	1 Year
Casdin Capital, LLC	0	One Year
B Group, Inc.	1,778,755	For
RICE HALL JAMES & ASSOCIATES, LLC	0	1 Year
DE Shaw	0	One Year
Northern Trust	0	1 Year
Aberdeen	0	One Year
Sands Capital Alternatives, LLC	0	One Year
Voya	0	One Year
Victory Capital	0	One Year

Showing the 25 largest of 181 asset managers. See all 181 in the interactive database.

3. To elect the Board's Class III Director nominees, Sean P. Nolan and Laura Sepp-Lorenzino, Ph.D. to the Board of Directors to hold office until the 2029 Annual Meeting of Stockholders: Laura Sepp-Lorenzino, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

73% Majority: yes · of votes cast

FOR 73%WITHHELD 27%

FOR: 150,094,517WITHHELD: 54,790,109

Taysha Gene Therapies, Inc.’s own tally for this item (“Elect Director: Laura Sepp-Lorenzino, Ph.D.”): 150,094,517 for, 54,790,109 withheld, per its Form 8-K filed 2026-06-02 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 287,276,885 outstanding shares: 52.2% for, 19% withheld (71% of the company cast a for/withheld vote).

The 47 asset managers below cast 100% of the shares they voted on this item FOR (27,854,046 for, 0 against).

FOR 75%ABSTAIN 25%

FOR: 27,854,046 (75.0%)ABSTAIN: 9,307,502 (25.0%)

Largest asset managers voting on “To elect the Board's Class III Director nominees, Sean P. Nolan and Laura Sepp-Lorenzino, Ph.D. to the Board o” at Taysha Gene Therapies, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Fidelity	12,925,102	120,030	For
Vanguard	12,298,759	69,526	For
BlackRock	0	4,478,489	Abstain
State Street	1,595	1,938,207	Abstain
Charles Schwab	1,809,755	0	For
TIAA	0	503,136	Abstain
Equitable	0	477,281	Abstain
Victory Capital	0	399,073	Abstain
Lincoln Financial	0	257,568	Abstain
Voya	240,227	0	For
ProShares	0	177,088	Abstain
CLEARWATER INVESTMENT TRUST	157,524	0	For
ALPS ETF Trust	0	136,680	Abstain
AIG/SunAmerica	0	114,359	Abstain
Goldman Sachs	106,455	0	For
Global X	103,188	0	For
Northern Trust	0	99,638	Abstain
Invesco	0	85,578	Abstain
FundVantage Trust	82,734	0	For
Pacific Life	0	71,983	Abstain
Brighthouse	0	70,688	Abstain
John Hancock	0	58,544	Abstain
MASTER INVESTMENT PORTFOLIO	0	48,948	Abstain
ETFis Series Trust I	0	44,862	Abstain
Bridge Builder Trust	0	42,525	Abstain

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

4. To elect the Board's Class III Director nominees, Sean P. Nolan and Laura Sepp-Lorenzino, Ph.D. to the Board of Directors to hold office until the 2029 Annual Meeting of Stockholders: Sean P. Nolan

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

83% Majority: yes · of votes cast

FOR 83%WITHHELD 17%

FOR: 169,142,295WITHHELD: 35,742,331

Taysha Gene Therapies, Inc.’s own tally for this item (“Elect Director: Sean P. Nolan”): 169,142,295 for, 35,742,331 withheld, per its Form 8-K filed 2026-06-02 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 287,276,885 outstanding shares: 59% for, 12% withheld (71% of the company cast a for/withheld vote).

The 47 asset managers below cast 100% of the shares they voted on this item FOR (35,557,327 for, 0 against).

FOR 96%

FOR: 35,557,327 (95.7%)ABSTAIN: 1,604,221 (4.3%)

Largest asset managers voting on “To elect the Board's Class III Director nominees, Sean P. Nolan and Laura Sepp-Lorenzino, Ph.D. to the Board o” at Taysha Gene Therapies, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Fidelity	12,986,432	58,700	For
Vanguard	12,289,746	78,539	For
BlackRock	4,478,489	0	For
State Street	1,935,435	4,367	For
Charles Schwab	1,809,755	0	For
TIAA	503,136	0	For
Equitable	477,281	0	For
Victory Capital	0	399,073	Abstain
Lincoln Financial	149,600	107,968	For
Voya	0	240,227	Abstain
ProShares	0	177,088	Abstain
CLEARWATER INVESTMENT TRUST	157,524	0	For
ALPS ETF Trust	0	136,680	Abstain
AIG/SunAmerica	0	114,359	Abstain
Goldman Sachs	106,455	0	For
Global X	103,188	0	For
Northern Trust	99,638	0	For
Invesco	85,578	0	For
FundVantage Trust	82,734	0	For
Pacific Life	71,983	0	For
Brighthouse	0	70,688	Abstain
John Hancock	0	58,544	Abstain
MASTER INVESTMENT PORTFOLIO	48,948	0	For
ETFis Series Trust I	0	44,862	Abstain
Bridge Builder Trust	42,525	0	For

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

5. To ratify the selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for the year ending December 31, 2026.

AUDIT-RELATEDMajority of the votes cast: yes

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 243,814,085AGAINST: 25,551

Taysha Gene Therapies, Inc.’s own tally for this item (“Elect Director: Ratification of selection of Deloitte & Touche LLP”): 243,814,085 for, 25,551 against, per its Form 8-K filed 2026-06-02 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 287,276,885 outstanding shares: 85% for, 0.1% against (85% of the company cast a for/against vote).

The 47 asset managers below cast 100% of the shares they voted on this item FOR (37,161,548 for, 0 against).

FOR 100%

FOR: 37,161,548 (100.0%)

Largest asset managers voting on “To ratify the selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the indep” at Taysha Gene Therapies, Inc., 2025-2026
Asset manager	For	Vote
Fidelity	13,045,132	For
Vanguard	12,368,284	For
BlackRock	4,478,489	For
State Street	1,939,802	For
Charles Schwab	1,809,755	For
TIAA	503,136	For
Equitable	477,281	For
Victory Capital	399,073	For
Lincoln Financial	257,568	For
Voya	240,227	For
ProShares	177,088	For
CLEARWATER INVESTMENT TRUST	157,524	For
ALPS ETF Trust	136,680	For
AIG/SunAmerica	114,359	For
Goldman Sachs	106,455	For
Global X	103,188	For
Northern Trust	99,638	For
Invesco	85,578	For
FundVantage Trust	82,734	For
Pacific Life	71,983	For
Brighthouse	70,688	For
John Hancock	58,544	For
MASTER INVESTMENT PORTFOLIO	48,948	For
ETFis Series Trust I	44,862	For
Bridge Builder Trust	42,525	For

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

6. Advisory Vote on Say on Pay Frequency

SECTION 14A SAY-ON-PAY VOTES

— fund support · no official result

1 YEAR 88%12%

No shares were cast for or against this item by the managers below — every disclosed position was an abstention or was not voted.

1 YEAR: 789,051 (88.3%)ONE YEAR: 104,883 (11.7%)

Largest asset managers voting on “Advisory Vote on Say on Pay Frequency” at Taysha Gene Therapies, Inc., 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
Granahan Investment Management, LLC	0	0	0	0	1 Year
WEXFORD CAPITAL LP	0	0	0	0	One Year
FORUM FUNDS II	0	0	0	0	One Year
APG Asset Management US Inc.	0	0	0	0	One Year
Coyle Financial Counsel LLC	0	0	0	0	1 Year

7. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

82% Majority: yes · of votes cast

FOR 82%AGAINST 18%

FOR: 168,142,551AGAINST: 36,396,784

The 5 asset managers below cast 0.1% of the shares they voted on this item FOR (410 for, 851,724 against).

AGAINST 95%

FOR: 410 (0.0%)AGAINST: 851,724 (95.3%)ABSTAIN: 41,800 (4.7%)

Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at Taysha Gene Therapies, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Granahan Investment Management, LLC	0	788,641	0	Against
WEXFORD CAPITAL LP	0	51,583	0	Against
FORUM FUNDS II	0	0	41,800	Abstain
APG Asset Management US Inc.	0	11,500	0	Against
Coyle Financial Counsel LLC	410	0	0	For

Largest Taysha Gene Therapies, Inc. shareholders voting in 2025-2026

Ranked by the number of Taysha Gene Therapies, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 287,276,885 shares outstanding at the time of that meeting.

Top Taysha Gene Therapies, Inc. shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	Fidelity	9.28%
2	RA CAPITAL MANAGEMENT, L.P.	8.20%
3	Avoro Capital Advisors LLC	7.10%
4	Vanguard	4.93%
5	Vestal Point Capital, LP	4.22%
6	RTW INVESTMENTS, LP	4.05%
7	BlackRock	3.75%
8	Polar Capital Holdings Plc	3.73%
9	Octagon Capital Advisors LP	3.08%
10	Siren, L.L.C.	3.07%

Reported Taysha Gene Therapies, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Taysha Gene Therapies, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
Goldman Sachs	7.79%	13F
RTW Investments, LP	7.20%	13G
BlackRock	6.39%	13F
Morgan Stanley	6.29%	13F
FMR (Fidelity)	4.99%	13F
Vanguard Group	4.62%	13F
State Street	3.90%	13F
Geode Capital	1.93%	13F
D.E. Shaw	1.54%	13F
Millennium Management	1.14%	13F

Percentages above are of 287,276,885 shares outstanding, as reported by Taysha Gene Therapies, Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Taysha Gene Therapies, Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At Taysha Gene Therapies, Inc.'s shareholder meeting held 2026-06-01, in the 2025-2026 proxy season, 188 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,205 separate fund positions. Their filings are grouped here into 7 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE… — FOR was 82% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Taysha Gene Therapies, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-02.

Taysha Gene Therapies, Inc. proxy season coverage: 2025-2026 (this page).